The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1016/j.bjorl.2017.10.005 http://hdl.handle.net/11449/177059 |
Resumo: | Introduction: Endogenous thyroid-stimulating hormone-stimulated thyroglobulin collected after total thyroidectomy is a useful predictor of better prognosis in patients with differentiated thyroid carcinomas in general, but studies with microcarcinomas are scarce. Objective: To assess whether the first postoperative stimulated thyroglobulin measurement is a prognostic factor in patients with microcarcinoma. Methods: The medical data of 150 differentiated thyroid carcinoma patients were studied retrospectively, and 54 (36%) cases with microcarcinoma were selected. The first postoperative stimulated thyroglobulin (1st stimulated thyroglobulin), measured after thyroidectomy, initial presentation data, and microcarcinomas treatment were assessed regarding outcome. Worse prognosis was defined as neoplasm persistence/recurrence. Results: Persistence/recurrence occurred in 27.6% of the cases. These patients were identified according to the following parameters: receiving more than one 131iodine dose (100% vs. 0%; p <0.0001); accumulated 131iodine dose (232.14±99.09 vs. 144±33.61mCi; p <0.0001); presented active disease in the last assessment (53.3% vs. 0%; p <0.0001); follow-up time (103.07±61.27 vs. 66.85±70.14 months; p =0.019); and 1st stimulated thyroglobulin (19.01±44.18 vs. 2.19±2.54ng/dL; p <0.0001). After multivariate logistic regression, only the 1stSTg [odds ratio=1.242; 95% confidence interval: 1.022-1.509; p =0.029] and follow-up time (odds ratio=1.027; 95% confidence interval: 1.007-1.048; p =0.007) were independent predictors of risk of persistence/recurrence. The cutoff point of 1.6ng/dL for the 1st stimulated thyroglobulin was significantly associated with disease persistence/recurrence [area under the curve=0.713 (p =0.019)]. Conclusion: The first stimulated thyroglobulin predicted disease persistence/recurrence in patients with microcarcinoma. |
id |
UNSP_1d66cbd36be324aaf19f066fa2ac111d |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/177059 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomasBiological markersClinical evolutionPrognosisThyroglobulinThyroid neoplasmsIntroduction: Endogenous thyroid-stimulating hormone-stimulated thyroglobulin collected after total thyroidectomy is a useful predictor of better prognosis in patients with differentiated thyroid carcinomas in general, but studies with microcarcinomas are scarce. Objective: To assess whether the first postoperative stimulated thyroglobulin measurement is a prognostic factor in patients with microcarcinoma. Methods: The medical data of 150 differentiated thyroid carcinoma patients were studied retrospectively, and 54 (36%) cases with microcarcinoma were selected. The first postoperative stimulated thyroglobulin (1st stimulated thyroglobulin), measured after thyroidectomy, initial presentation data, and microcarcinomas treatment were assessed regarding outcome. Worse prognosis was defined as neoplasm persistence/recurrence. Results: Persistence/recurrence occurred in 27.6% of the cases. These patients were identified according to the following parameters: receiving more than one 131iodine dose (100% vs. 0%; p <0.0001); accumulated 131iodine dose (232.14±99.09 vs. 144±33.61mCi; p <0.0001); presented active disease in the last assessment (53.3% vs. 0%; p <0.0001); follow-up time (103.07±61.27 vs. 66.85±70.14 months; p =0.019); and 1st stimulated thyroglobulin (19.01±44.18 vs. 2.19±2.54ng/dL; p <0.0001). After multivariate logistic regression, only the 1stSTg [odds ratio=1.242; 95% confidence interval: 1.022-1.509; p =0.029] and follow-up time (odds ratio=1.027; 95% confidence interval: 1.007-1.048; p =0.007) were independent predictors of risk of persistence/recurrence. The cutoff point of 1.6ng/dL for the 1st stimulated thyroglobulin was significantly associated with disease persistence/recurrence [area under the curve=0.713 (p =0.019)]. Conclusion: The first stimulated thyroglobulin predicted disease persistence/recurrence in patients with microcarcinoma.Universidade Estadual Paulista Júlio de Mesquita Filho (Unesp), Faculdade de Medicina de Botucatu, Departamento de Medicina Interna, Botucatu, SP, BrazilUniversidade Estadual Paulista Júlio de Mesquita Filho (Unesp), Faculdade de Medicina de Botucatu, Departamento de Oftalmologia, Otorrinolaringologia e Cirurgia de Cabeça e Pescoço, Botucatu, SP, BrazilUniversidade Estadual Paulista Júlio de Mesquita Filho (Unesp), Faculdade de Medicina de Botucatu, Departamento de Patologia, Botucatu, SP, BrazilUniversidade Estadual Paulista Júlio de Mesquita Filho (Unesp), Faculdade de Medicina de Botucatu, Departamento de Doenças Tropicais e Diagnóstico por Imagem, Botucatu, SP, BrazilUniversidade Estadual Paulista Júlio de Mesquita Filhos (Unesp), Instituto de Biociências, Departamento de Bioestatística, Botucatu, SP, BrazilUniversidade Estadual Paulista (Unesp)Amui, Isabela de OliveiraTagliarini, José VicenteCastilho, Emanuel C.Marques, Mariângela de AlencarKiy, YoshioCorrente, José EduardoMazeto, Gláucia M.F.S.2018-12-11T17:23:41Z2018-12-11T17:23:41Z2017-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://dx.doi.org/10.1016/j.bjorl.2017.10.005Brazilian Journal of Otorhinolaryngology.1808-86861808-8694http://hdl.handle.net/11449/17705910.1016/j.bjorl.2017.10.0052-s2.0-850340586392-s2.0-85034058639.pdf7528116925519142Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengBrazilian Journal of Otorhinolaryngology0,443info:eu-repo/semantics/openAccess2024-09-03T13:15:04Zoai:repositorio.unesp.br:11449/177059Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462024-09-03T13:15:04Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas |
title |
The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas |
spellingShingle |
The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas Amui, Isabela de Oliveira Biological markers Clinical evolution Prognosis Thyroglobulin Thyroid neoplasms |
title_short |
The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas |
title_full |
The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas |
title_fullStr |
The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas |
title_full_unstemmed |
The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas |
title_sort |
The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas |
author |
Amui, Isabela de Oliveira |
author_facet |
Amui, Isabela de Oliveira Tagliarini, José Vicente Castilho, Emanuel C. Marques, Mariângela de Alencar Kiy, Yoshio Corrente, José Eduardo Mazeto, Gláucia M.F.S. |
author_role |
author |
author2 |
Tagliarini, José Vicente Castilho, Emanuel C. Marques, Mariângela de Alencar Kiy, Yoshio Corrente, José Eduardo Mazeto, Gláucia M.F.S. |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Amui, Isabela de Oliveira Tagliarini, José Vicente Castilho, Emanuel C. Marques, Mariângela de Alencar Kiy, Yoshio Corrente, José Eduardo Mazeto, Gláucia M.F.S. |
dc.subject.por.fl_str_mv |
Biological markers Clinical evolution Prognosis Thyroglobulin Thyroid neoplasms |
topic |
Biological markers Clinical evolution Prognosis Thyroglobulin Thyroid neoplasms |
description |
Introduction: Endogenous thyroid-stimulating hormone-stimulated thyroglobulin collected after total thyroidectomy is a useful predictor of better prognosis in patients with differentiated thyroid carcinomas in general, but studies with microcarcinomas are scarce. Objective: To assess whether the first postoperative stimulated thyroglobulin measurement is a prognostic factor in patients with microcarcinoma. Methods: The medical data of 150 differentiated thyroid carcinoma patients were studied retrospectively, and 54 (36%) cases with microcarcinoma were selected. The first postoperative stimulated thyroglobulin (1st stimulated thyroglobulin), measured after thyroidectomy, initial presentation data, and microcarcinomas treatment were assessed regarding outcome. Worse prognosis was defined as neoplasm persistence/recurrence. Results: Persistence/recurrence occurred in 27.6% of the cases. These patients were identified according to the following parameters: receiving more than one 131iodine dose (100% vs. 0%; p <0.0001); accumulated 131iodine dose (232.14±99.09 vs. 144±33.61mCi; p <0.0001); presented active disease in the last assessment (53.3% vs. 0%; p <0.0001); follow-up time (103.07±61.27 vs. 66.85±70.14 months; p =0.019); and 1st stimulated thyroglobulin (19.01±44.18 vs. 2.19±2.54ng/dL; p <0.0001). After multivariate logistic regression, only the 1stSTg [odds ratio=1.242; 95% confidence interval: 1.022-1.509; p =0.029] and follow-up time (odds ratio=1.027; 95% confidence interval: 1.007-1.048; p =0.007) were independent predictors of risk of persistence/recurrence. The cutoff point of 1.6ng/dL for the 1st stimulated thyroglobulin was significantly associated with disease persistence/recurrence [area under the curve=0.713 (p =0.019)]. Conclusion: The first stimulated thyroglobulin predicted disease persistence/recurrence in patients with microcarcinoma. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-01-01 2018-12-11T17:23:41Z 2018-12-11T17:23:41Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1016/j.bjorl.2017.10.005 Brazilian Journal of Otorhinolaryngology. 1808-8686 1808-8694 http://hdl.handle.net/11449/177059 10.1016/j.bjorl.2017.10.005 2-s2.0-85034058639 2-s2.0-85034058639.pdf 7528116925519142 |
url |
http://dx.doi.org/10.1016/j.bjorl.2017.10.005 http://hdl.handle.net/11449/177059 |
identifier_str_mv |
Brazilian Journal of Otorhinolaryngology. 1808-8686 1808-8694 10.1016/j.bjorl.2017.10.005 2-s2.0-85034058639 2-s2.0-85034058639.pdf 7528116925519142 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Brazilian Journal of Otorhinolaryngology 0,443 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
repositoriounesp@unesp.br |
_version_ |
1810021378851602432 |